Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations.
Adult
Attention deficit disorder with hyperactivity
Continuity of patient care, service delivery, National Institute of health and care excellence (NICE)
Delivery of health care, integrated
Delivery of healthcare
Primary health care
Secondary care
Tertiary healthcare
UK adult ADHD network (UKAAN)
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
17
11
2021
accepted:
27
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
ADHD in adults is a common and debilitating neurodevelopmental mental health condition. Yet, diagnosis, clinical management and monitoring are frequently constrained by scarce resources, low capacity in specialist services and limited awareness or training in both primary and secondary care. As a result, many people with ADHD experience serious barriers in accessing the care they need. Professionals across primary, secondary, and tertiary care met to discuss adult ADHD clinical care in the United Kingdom. Discussions identified constraints in service provision, and service delivery models with potential to improve healthcare access and delivery. The group aimed to provide a roadmap for improving access to ADHD treatment, identifying avenues for improving provision under current constraints, and innovating provision in the longer-term. National Institute for Health and Care Excellence (NICE) guidelines were used as a benchmark in discussions. The group identified three interrelated constraints. First, inconsistent interpretation of what constitutes a 'specialist' in the context of delivering ADHD care. Second, restriction of service delivery to limited capacity secondary or tertiary care services. Third, financial limitations or conflicts which reduce capacity and render transfer of care between healthcare sectors difficult. The group recommended the development of ADHD specialism within primary care, along with the transfer of routine and straightforward treatment monitoring to primary care services. Longer term, ADHD care pathways should be brought into line with those for other common mental health disorders, including treatment initiation by appropriately qualified clinicians in primary care, and referral to secondary mental health or tertiary services for more complex cases. Long-term plans in the NHS for more joined up and flexible provision, using a primary care network approach, could invest in developing shared ADHD specialist resources. The relegation of adult ADHD diagnosis, treatment and monitoring to specialist tertiary and secondary services is at odds with its high prevalence and chronic course. To enable the cost-effective and at-scale access to ADHD treatment that is needed, general adult mental health and primary care must be empowered to play a key role in the delivery of quality services for adults with ADHD.
Sections du résumé
BACKGROUND
ADHD in adults is a common and debilitating neurodevelopmental mental health condition. Yet, diagnosis, clinical management and monitoring are frequently constrained by scarce resources, low capacity in specialist services and limited awareness or training in both primary and secondary care. As a result, many people with ADHD experience serious barriers in accessing the care they need.
METHODS
Professionals across primary, secondary, and tertiary care met to discuss adult ADHD clinical care in the United Kingdom. Discussions identified constraints in service provision, and service delivery models with potential to improve healthcare access and delivery. The group aimed to provide a roadmap for improving access to ADHD treatment, identifying avenues for improving provision under current constraints, and innovating provision in the longer-term. National Institute for Health and Care Excellence (NICE) guidelines were used as a benchmark in discussions.
RESULTS
The group identified three interrelated constraints. First, inconsistent interpretation of what constitutes a 'specialist' in the context of delivering ADHD care. Second, restriction of service delivery to limited capacity secondary or tertiary care services. Third, financial limitations or conflicts which reduce capacity and render transfer of care between healthcare sectors difficult. The group recommended the development of ADHD specialism within primary care, along with the transfer of routine and straightforward treatment monitoring to primary care services. Longer term, ADHD care pathways should be brought into line with those for other common mental health disorders, including treatment initiation by appropriately qualified clinicians in primary care, and referral to secondary mental health or tertiary services for more complex cases. Long-term plans in the NHS for more joined up and flexible provision, using a primary care network approach, could invest in developing shared ADHD specialist resources.
CONCLUSIONS
The relegation of adult ADHD diagnosis, treatment and monitoring to specialist tertiary and secondary services is at odds with its high prevalence and chronic course. To enable the cost-effective and at-scale access to ADHD treatment that is needed, general adult mental health and primary care must be empowered to play a key role in the delivery of quality services for adults with ADHD.
Identifiants
pubmed: 36221085
doi: 10.1186/s12888-022-04290-7
pii: 10.1186/s12888-022-04290-7
pmc: PMC9553294
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
640Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
BMC Health Serv Res. 2019 Jul 9;19(1):468
pubmed: 31288805
BMC Psychiatry. 2018 Sep 4;18(1):281
pubmed: 30180832
J Atten Disord. 2019 Apr;23(6):624-634
pubmed: 27255536
BMC Fam Pract. 2013 Dec 30;14:202
pubmed: 24373254
J Psychiatr Res. 2020 Apr;123:21-30
pubmed: 32014701
BMJ Open. 2016 Jun 13;6(6):e010508
pubmed: 27297009
Clin Psychol Rev. 2011 Apr;31(3):328-41
pubmed: 21382538
J Child Psychol Psychiatry. 2019 Apr;60(4):333-352
pubmed: 30843223
BJPsych Open. 2020 Jul 29;6(4):e76
pubmed: 32723405
BMC Psychiatry. 2013 Jul 10;13:186
pubmed: 23842080
Am J Psychiatry. 2015 Oct;172(10):967-77
pubmed: 25998281
BMC Med. 2012 Sep 04;10:99
pubmed: 22947230
BJPsych Open. 2020 Jan 06;6(1):e7
pubmed: 31902389
Prev Med. 2011 Mar-Apr;52(3-4):218-22
pubmed: 21241728
N Engl J Med. 2012 Nov 22;367(21):2006-14
pubmed: 23171097
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1028-1040
pubmed: 17667481
Neuropsychiatr Dis Treat. 2018 Sep 17;14:2379-2387
pubmed: 30271154
JAMA Psychiatry. 2015 Dec;72(12):1199-210
pubmed: 26536057
J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):9-21
pubmed: 21156266
Neuropsychiatr Dis Treat. 2020 May 21;16:1309-1319
pubmed: 32547034
J Psychopharmacol. 2015 Jan;29(1):39-42
pubmed: 25237121
Neurotherapeutics. 2012 Jul;9(3):490-9
pubmed: 22976615
Br J Psychiatry. 2020 Nov;217(5):616-622
pubmed: 31159893
J Am Acad Child Adolesc Psychiatry. 2016 Nov;55(11):931-936
pubmed: 27806860
Neurosci Biobehav Rev. 2018 Jan;84:63-71
pubmed: 29162520
AIMS Public Health. 2014 Mar 17;1(1):33-42
pubmed: 29666825
Biol Psychiatry. 2016 Dec 15;80(12):916-922
pubmed: 27086545
J Child Psychol Psychiatry. 2014 Aug;55(8):878-85
pubmed: 25158998
Lancet Psychiatry. 2018 Sep;5(9):717-726
pubmed: 30054261
Nat Genet. 2019 Jan;51(1):63-75
pubmed: 30478444
Neurology. 2018 Mar 27;90(13):e1104-e1110
pubmed: 29476037
Br J Gen Pract. 2017 Nov;67(664):e792-e799
pubmed: 28947619
Arch Psychiatr Nurs. 2015 Feb;29(1):56-63
pubmed: 25634876
JAMA. 2016 Nov 1;316(17):1798-1807
pubmed: 27802545
Ir J Psychol Med. 2018 Sep;35(3):221-235
pubmed: 30124182
Psychol Med. 2015 Jan;45(2):247-58
pubmed: 25066071
Psychol Med. 2006 Feb;36(2):159-65
pubmed: 16420712
BMC Health Serv Res. 2008 Jun 23;8:135
pubmed: 18573214
J Psychiatr Res. 2015 Mar;62:92-100
pubmed: 25680235
Br J Psychiatry. 2016 Jun;208(6):548-55
pubmed: 26250744
JAMA Psychiatry. 2019 Nov 1;76(11):1141-1149
pubmed: 31389973
Am J Psychiatry. 1996 Sep;153(9):1143-6
pubmed: 8780416
Br J Psychiatry. 2010 Oct;197(4):305-12
pubmed: 20884954
BMC Psychiatry. 2010 Sep 03;10:67
pubmed: 20815868
Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65
pubmed: 27866355
JAMA Psychiatry. 2014 Mar;71(3):319-25
pubmed: 24477798
J Atten Disord. 2018 Apr;22(6):523-534
pubmed: 26396145
Lancet. 2015 May 30;385(9983):2190-6
pubmed: 25726514
Eur J Hosp Pharm. 2018 Jul;25(4):222-224
pubmed: 31157025
Br J Psychiatry. 2007 May;190:402-9
pubmed: 17470954
J Child Psychol Psychiatry. 2018 Sep;59(9):932-947
pubmed: 29083042
J Abnorm Child Psychol. 2013 Jan;41(1):27-41
pubmed: 22752720
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
J Psychopharmacol. 2007 Jan;21(1):10-41
pubmed: 17092962
Nervenarzt. 2003 Oct;74(10):939-46
pubmed: 14655655
Biol Psychiatry. 2019 Sep 1;86(5):335-343
pubmed: 31155139
CNS Spectr. 2015 Apr;20(2):112-21
pubmed: 24571924
Eur Psychiatry. 2017 Jul;44:198-207
pubmed: 28646732
BMC Psychiatry. 2015 Oct 13;15:242
pubmed: 26462666
J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2):192-202
pubmed: 16429090
Eur Psychiatry. 2019 Feb;56:14-34
pubmed: 30453134
BMC Health Serv Res. 2013 May 21;13:184
pubmed: 23692803
J Atten Disord. 2021 Nov;25(13):1783-1790
pubmed: 32697120
Lancet Psychiatry. 2018 Oct;5(10):824-835
pubmed: 30220514
Lancet Psychiatry. 2018 Feb;5(2):175-186
pubmed: 29033005
Br J Psychiatry. 2009 Mar;194(3):204-11
pubmed: 19252145
Eur Neuropsychopharmacol. 2016 Nov;26(11):1760-1767
pubmed: 27667705
Eur Psychiatry. 2019 Sep;61:41-48
pubmed: 31288209
Pediatrics. 2015 Apr;135(4):e994-1001
pubmed: 25733754
Br J Clin Pharmacol. 2016 Sep;82(3):858-68
pubmed: 27145886
PLoS One. 2018 Sep 26;13(9):e0204516
pubmed: 30256837
Am J Psychiatry. 2013 Mar;170(3):275-89
pubmed: 23360949
BMC Fam Pract. 2019 Nov 20;20(1):159
pubmed: 31747903
Child Adolesc Psychiatry Ment Health. 2013 Oct 11;7(1):34
pubmed: 24119376
Br J Gen Pract. 2017 Feb;67(655):e138-e147
pubmed: 28093422
Br J Psychiatry. 2009 Mar;194(3):273-7
pubmed: 19252159
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449
J Am Acad Child Adolesc Psychiatry. 2018 Jan;57(1):48-53
pubmed: 29301669
Psychol Med. 2020 Oct;50(13):2240-2253
pubmed: 31530292
Biol Psychiatry. 2009 Jan 1;65(1):46-54
pubmed: 19006789
Eur Child Adolesc Psychiatry. 2016 Sep;25(9):1007-17
pubmed: 26837866
Biol Psychiatry. 2020 Sep 15;88(6):452-458
pubmed: 31987492
Acta Psychiatr Scand. 2013 Jul;128(1):70-7
pubmed: 22943458
Atten Defic Hyperact Disord. 2019 Sep;11(3):255-262
pubmed: 30730035